Abstract
Perhaps the most difficult aspect of clinical oncology is that of monitoring, which demands great experience as well as skill since the assessment is often complicated by side issues. The monitoring process, which must usually be continued for many years, is concerned basically with the assessment of the response of the tumour to a therapy. Several factors are helpful in making such an assessment (see Table 1) but often the judgment is made on empirical grounds. Certain rules have been accepted to enable comparable information to be produced and to enhance the management of patients. These rules are concerned with the objective assessment of response and are based on a standardised terminology regarding the degree of response. Although the use of such guidelines is to be encouraged, there are often limitations imposed by the clinical progress in a particular patient.
Keywords
- Malignant Disease
- Vinca Alkaloid
- Constrictive Pericarditis
- Physical Debility
- Human Metastatic Breast Cancer
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207–214, 1981.
Haywood JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289–1294, 1977.
Gutterman JU, Blumenschein GR, Alexanian R, et al.: Leukocyte interferon induced tumour regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 93: 399–406, 1980.
Breur K: Growth rate and radiosensitivity of human tumours I. Growth rate of human tumours. Eur J Cancer 2: 157–171, 1966.
Peto R: Monitoring patients in clinical trials, pp 377–381. In: Cancer: assessment and monitoring, Symmington T, Williams AE, McVie JG (eds). Edinburgh: Churchill Livingstone, 1980.
Watson JV: What does ‘response’ in cancer chemotherapy really mean? Br Med J 283: 3437, 1981.
Staughton RCD: Cutaneous manifestations of malignancy. Br J Hosp Med 20: 38–47, 1978.
Croft P: Neuromuscular syndromes associated with malignant disease. Br J Hosp Med 17: 356–362, 1977.
Editorial. Nutrition and the patient with cancer. Br Med J 2: 846–847, 1978.
Editorial. Fever in malignant disease. Br Med J 1: 591–592, 1974.
Young CW: Studies on fever in malignant disease, pp 235–241. In: Fever, Lipton JM (ed). New York: Raven Press, 1980.
Maguire P: Psychiatric aspects of malignant disease. SK and F Publications 4 (2): 1–12, 1981.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Martinus Nijhoff Publishers, The Hague
About this chapter
Cite this chapter
Hancock, B.W., Neal, F.E. (1982). Clinical Assessment. In: Hancock, B.W. (eds) Assessment of Tumour Response. Developments in Oncology, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-7633-7_1
Download citation
DOI: https://doi.org/10.1007/978-94-009-7633-7_1
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-7635-1
Online ISBN: 978-94-009-7633-7
eBook Packages: Springer Book Archive